AXIM Biotechnologies, Inc.
AXIM
Rank in Stocks
#32886
AXIM Biotechnologies, Inc. specializes in the creation and distribution of... AXIM Biotechnologies, Inc. specializes in the creation and distribution of advanced diagnostic solutions for healthcare, focusing on critical areas such as SARS-CoV-2 (COVID-19), ocular health, and cancer treatment. The company is currently developing rapid diagnostic assays that quantify functional neutralizing antibodies, which are essential for preventing the SARS-CoV-2 virus from attaching to human cells. Additionally, it offers serological diagnostic tests designed to detect neutralizing antibodies, thereby assessing the body's adaptive immune response to the virus, and is developing tests to identify inflammation biomarkers for the effective management of COVID-19 patients. For eye health, AXIM is pioneering quick, quantitative tear tests to measure Matrix metalloproteinase-9, an inflammatory marker associated with dry eye disease. In its oncology pipeline, the firm is advancing SBI-183, an anti-metastatic compound engineered to inhibit tumor cell growth and block the spread of cancer, as well as SPX-1009, another anti-metastatic therapy aimed at determining the levels of quiescin sulfhydryl oxidase I. Established in 2010, the company was formerly known as Axim International Inc. before officially changing its name to AXIM Biotechnologies, Inc. in July 2014, and it is headquartered in San Diego, California.
Share Price
$0.003
Last synced: 2026-11-11
Market Cap
$1.05M
Change (1 day)
-6.25%
Change (1 year)
-78.57%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade AXIM Biotechnologies, Inc. (AXIM)
Category
Healthcare
Operating Margin for AXIM Biotechnologies, Inc. (AXIM)
Operating Margin as of November 2026 TTM: -268.08%
According to AXIM Biotechnologies, Inc.'s latest financial reports, its current operating margin (TTM) is -268.08%. At the end of 2025 the company had an operating margin of 0.00%.
Operating Margin history for AXIM Biotechnologies, Inc. from 2011 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -268.08% | 0.00% |
| 2025 | 0.00% | -100.00% |
| 2024 | -2,502.31% | -64.05% |
| 2023 | -6,960.98% | -86.72% |
| 2022 | -52,425.60% | 296.95% |
| 2021 | -13,207.09% | 0.00% |
| 2020 | 0.00% | -100.00% |
| 2019 | -813.73% | -68.39% |
| 2018 | -2,574.53% | -61.11% |
| 2017 | -6,619.48% | -17.14% |
| 2016 | -7,988.83% | -60.94% |
| 2015 | -20,451.26% | 0.00% |
| 2014 | 0.00% | -100.00% |
| 2013 | -411.77% | 1,097.35% |
| 2012 | -34.39% | 23.09% |
| 2011 | -27.94% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| -181.36% | -99.32% |
US
|
|
| 38.59% | -100.14% |
US
|
|
| -149.01% | -99.44% |
US
|
|
| 25.57% | -100.10% |
AU
|
|
| 31.23% | -100.12% |
BE
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about AXIM Biotechnologies, Inc.'s operating margin
What is AXIM Biotechnologies, Inc.'s operating margin?
AXIM Biotechnologies, Inc.'s operating margin is -268.08%, as of Nov 2026.
What was AXIM Biotechnologies, Inc.'s operating margin in 2025?
In 2025, AXIM Biotechnologies, Inc.'s operating margin was 0.00%, compared with -2,502.31% in 2024.
How has AXIM Biotechnologies, Inc.'s operating margin changed since 2020?
From 2020 to 2025, AXIM Biotechnologies, Inc.'s operating margin was highest in 2025 (0.00%) and lowest in 2022 (-52,425.60%).
How does AXIM Biotechnologies, Inc.'s operating margin compare with similar companies?
AXIM Biotechnologies, Inc.'s operating margin (-268.08%) is lower than that of all 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.